Go to the list of all blogs
Scott Bell's Avatar
published in Blogs
Nov 19, 2026
TickeronGET DAILY SIGNALS
Fortress Biotech (FBIO): Weighing the $11 Analyst Target and a Potential +480% Upside

Fortress Biotech (FBIO): Weighing the $11 Analyst Target and a Potential +480% Upside

Key Takeaways

  • The central stock price target used here is $11, the arithmetic mean of the two current, verifiable analyst price targets ($5 and $17).
  • Coverage is very thin: two firms — Alliance Global Partners ($5, Buy) and H.C. Wainwright ($17, Buy) — drive the estimate, producing an unusually wide low-to-high range of $5 to $17.
  • With shares trading near $1.90, reaching $11 would require a move of roughly 480%, a very large advance.
  • The strongest support for a higher valuation comes from commercial momentum in its dermatology franchise and a potential priority review voucher (PRV) windfall, while thin capitalization and a wide target dispersion are the biggest risks.
  • Readers can explore more context on the company's Major News, Today's Price Move, Forecast, and Earnings pages.

Analyst Price Targets and Consensus View

Fortress Biotech, Inc. (FBIO) is a Nasdaq-listed biopharmaceutical company, not an ETF. Its sell-side coverage is limited. The two credible, current targets reviewed are a $5 target from Alliance Global Partners (Scott Henry, Buy, reaffirmed in May 2026 after a lift from $4.50) and a $17 target from H.C. Wainwright (Joseph Pantginis, Buy, reaffirmed in February 2026). A separate Roth MKM target was cut to $12 back in August 2025 and is now outside a typical 12-month research horizon, so it is not used in the calculation.

Because these two current targets are so far apart, the average analyst price target of $11 sits between them rather than reflecting any genuine analyst consensus. No reputable source reports an official consensus of $11, and the figure should be read as a mathematical midpoint, not a forecast. The $5–$17 dispersion reflects fundamentally different assumptions: the lower view emphasizes near-term execution risk, while H.C. Wainwright's higher view leans on a potential PRV windfall and "de-risked" economics for its Zycubo program.

Current Market Position and Path Toward the Target

FBIO has recently traded near $1.90, within a 52-week range of roughly $1.64 to $4.53, with a market capitalization around $63–66 million. Reaching the $11 target would require an advance of about 480% — by any standard, a very large move. That is not a gradual re-rating; it implies a multi-fold expansion in the company's market value.

The path toward such a level would most plausibly depend on a step-change in fundamentals rather than sentiment alone. Fortress reported third-quarter 2026 results in November, with GAAP EPS (earnings per share) of -$0.23 beating estimates by $0.04, while revenue of $19.16 million came in below expectations. Management emphasized continued momentum in Emrosi, its commercial rosacea treatment, which is central to the company's dermatology-led revenue story. I also checked this using Tickeron’s AI Screener to see how the stock compares to others in the industry.

What Could Support a Move Toward the Target

  • Commercial execution: Growing Emrosi (rosacea) sales and the established dermatology portfolio (Ximino, Targadox, Exelderm, Ceracade, Luxamend) provide recurring revenue.
  • PRV potential: H.C. Wainwright's $17 thesis explicitly cites a priority review voucher windfall, which can generate substantial one-time, non-dilutive cash.
  • Pipeline optionality: Programs such as CUTX-101 for Menkes disease, for which the FDA accepted a resubmission, offer catalysts beyond the current commercial base.
  • Low valuation base: With a price-to-book ratio below 1 and a market cap under $70 million, even moderate operational improvements can move the shares sharply.

What Could Prevent the Target From Being Reached

  • Thin analyst coverage: Only two current targets underpin the figure, so there is no broad professional validation of the $11 midpoint.
  • Revenue misses and losses: The recent quarterly revenue shortfall and negative EPS highlight execution uncertainty in a small-cap biopharma.
  • Wide target dispersion: The $5–$17 range means even the "average" conceals very different risk assessments.
  • Dilution risk: A sub-$70 million market cap biotech often finances operations through equity raises, which can pressure the share price.
  • Elevated short interest: Reported short interest near 20% of float reflects meaningful skepticism that would need to be overcome.

Technical Levels and Market Structure

The shares have been in a broad decline, trading well below the 52-week high of $4.53 and near the 52-week low of $1.64. The $1.64 area is a key support level, while the prior peak near $4.53 marks a major resistance level well before any move toward $11. Psychologically, $2 and $5 stand out as intermediate thresholds, with the $5 Alliance Global Partners target coinciding with a meaningful round-number zone. The current structure shows a stock still attempting to establish a durable base rather than one confirming an uptrend.

Time Horizon and What Investors Should Monitor

Analyst targets generally reflect a research horizon of roughly 12 months, though with only two active firms there is little basis to infer a precise consensus time frame. Key items to watch include quarterly earnings and Emrosi prescription and revenue trends, any regulatory decisions on CUTX-101 or other pipeline assets, updates on the potential PRV, changes to analyst ratings or targets, and capital-raising activity given the company's size. Cash position and operating-loss trajectory will also matter for judging whether the equity can fund its path without heavy dilution. From what I see, automated signals can help track these developments efficiently.

Final Assessment

The $11 figure for FBIO is a calculated midpoint of two far-apart analyst targets — $5 and $17 — not a published consensus or a prediction. With shares near $1.90, the required move is roughly 480%, an exceptionally large advance. The most constructive case rests on Emrosi growth, a possible PRV windfall, and pipeline catalysts, while the principal obstacles are weak revenue execution, ongoing losses, thin coverage, dilution risk, and heavy short interest. The $1.64 low and $4.53 high frame the market's current view. Given the extreme dispersion between the two active targets, the realistic question for investors is less whether $11 is reachable and more which of the two very different outlooks — cautious or bullish — proves closer to the company's actual trajectory.

Using AI Tools in My Research

Beyond manual research, I find Tickeron's AI Daily Buy/Sell Signals helpful for monitoring volatile small caps like FBIO. These AI-driven signals scan thousands of stocks continuously and flag Buy, Sell, or Hold ideas based on technicals and market shifts. They complement fundamental work by highlighting potential turning points without replacing it, allowing me to stay on top of fast-moving names more efficiently.

Disclaimer

The information on this webpage is provided for general informational and educational purposes only and is not intended as investment advice, a recommendation to purchase or sell any security, or an offer or solicitation related to investments. It does not consider your personal financial situation, goals, or risk profile, and all investing carries inherent risks, including the possibility of losing your entire investment. For more details, please review our full disclaimer.

Disclaimers and Limitations

Related Ticker: FBIO

Contributor

Scott Bell's AvatarScott Bell|Expert

I’m a trader and independent researcher. My interest lies at the intersection of financial markets, algorithms, and capital management. I develop data-driven tools and strategies and study algorithmic approaches to market analysis. I help turn complex market data into clear insights and practical systems. I believe technology should support, not replace, investment thinking


FBIO in upward trend: price may ascend as a result of having broken its lower Bollinger Band on November 16, 2026

FBIO may jump back above the lower band and head toward the middle band. Traders may consider buying the stock or exploring call options. In 30 of 35 cases where FBIO's price broke its lower Bollinger Band, its price rose further in the following month. The odds of a continued upward trend are 86%.

Price Prediction Chart

Technical Analysis (Indicators)

Bullish Trend Analysis

The RSI Oscillator points to a transition from a downward trend to an upward trend -- in cases where FBIO's RSI Indicator exited the oversold zone, 32 of 42 resulted in an increase in price. Tickeron's analysis proposes that the odds of a continued upward trend are 76%.

The Stochastic Oscillator suggests the stock price trend may be in a reversal from a downward trend to an upward trend. 56 of 69 cases where FBIO's Stochastic Oscillator exited the oversold zone resulted in an increase in price. Tickeron's analysis proposes that the odds of a continued upward trend are 81%.

The Moving Average Convergence Divergence (MACD) for FBIO just turned positive on October 20, 2026. Looking at past instances where FBIO's MACD turned positive, the stock continued to rise in 42 of 51 cases over the following month. The odds of a continued upward trend are 82%.

Following a +10.53% 3-day Advance, the price is estimated to grow further. Considering data from situations where FBIO advanced for three days, in 204 of 253 cases, the price rose further within the following month. The odds of a continued upward trend are 81%.

Bearish Trend Analysis

The Momentum Indicator moved below the 0 level on November 12, 2026. You may want to consider selling the stock, shorting the stock, or exploring put options on FBIO as a result. In 70 of 86 cases where the Momentum Indicator fell below 0, the stock fell further within the subsequent month. The odds of a continued downward trend are 81%.

Following a 3-day decline, the stock is projected to fall further. Considering past instances where FBIO declined for three days, the price rose further in 50 of 62 cases within the following month. The odds of a continued downward trend are 83%.

The Aroon Indicator for FBIO entered a downward trend on November 17, 2026. This could indicate a strong downward move is ahead for the stock. Traders may want to consider selling the stock or buying put options.

Fundamental Analysis (Ratings)

The Tickeron SMR rating for this company is 14 (best 1 - 100 worst), indicating very strong sales and a profitable business model. SMR (Sales, Margin, Return on Equity) rating is based on comparative analysis of weighted Sales, Income Margin and Return on Equity values compared against S&P 500 index constituents. The weighted SMR value is a proprietary formula developed by Tickeron and represents an overall profitability measure for a stock.

The Tickeron Valuation Rating of 58 (best 1 - 100 worst) indicates that the company is fair valued in the industry. This rating compares market capitalization estimated by our proprietary formula with the current market capitalization. This rating is based on the following metrics, as compared to industry averages: P/B Ratio (0.376) is normal, around the industry mean (3.592). P/E Ratio (0.569) is within average values for comparable stocks, (-1.190). Projected Growth (PEG Ratio) (0.000) is also within normal values, averaging (9.059). Dividend Yield (0.000) settles around the average of (131.305) among similar stocks. P/S Ratio (1.145) is also within normal values, averaging (442.120).

The Tickeron Price Growth Rating for this company is 75 (best 1 - 100 worst), indicating slightly worse than average price growth. FBIO’s price grows at a lower rate over the last 12 months as compared to S&P 500 index constituents.

The Tickeron PE Growth Rating for this company is 77 (best 1 - 100 worst), pointing to worse than average earnings growth. The PE Growth rating is based on a comparative analysis of stock PE ratio increase over the last 12 months compared against S&P 500 index constituents.

The Tickeron Profit vs. Risk Rating rating for this company is 100 (best 1 - 100 worst), indicating that the returns do not compensate for the risks. FBIO’s unstable profits reported over time resulted in significant Drawdowns within these last five years. A stable profit reduces stock drawdown and volatility. The average Profit vs. Risk Rating rating for the industry is 94, placing this stock worse than average.

Notable companies

The most notable companies in this group are Moderna (NASDAQ:MRNA), Regeneron Pharmaceuticals (NASDAQ:REGN), Incyte Corp (NASDAQ:INCY), Exelixis (NASDAQ:EXEL), Arrowhead Pharmaceuticals (NASDAQ:ARWR), Sarepta Therapeutics (NASDAQ:SRPT), Novavax (NASDAQ:NVAX), Nektar Therapeutics (NASDAQ:NKTR), Inovio Pharmaceuticals (NASDAQ:INO), Cel-Sci Corp (ASE:CVM).

Industry description

Biotechnology involves genetic or protein engineering to produce medicines/therapies for treating and preventing ailments. The industry also provides crucial ingredients for diagnostics. This multi-billion-dollar industry is heavily focused on research and development, as companies attempt to continually come up with cutting-edge solutions for health. New discoveries for the treatment of diseases provide opportunities for growth for a company in this industry. Discoveries, however, must pass the regulatory approval from the U.S. Food and Drug Administration (FDA) before they can make it to markets. Amgen Inc., Gilead Sciences, Inc. and Celgene Corporation are examples of companies in this industry.

Market Cap

The average market capitalization across the Biotechnology Industry is 2.24B. The market cap for tickers in the group ranges from 58 to 138.67B. VRTX holds the highest valuation in this group at 138.67B. The lowest valued company is SEELQ at 58.

High and low price notable news

The average weekly price growth across all stocks in the Biotechnology Industry was -6%. For the same Industry, the average monthly price growth was -12%, and the average quarterly price growth was -25%. SLS experienced the highest price growth at 113%, while CUE experienced the biggest fall at -74%.

Volume

The average weekly volume growth across all stocks in the Biotechnology Industry was 19%. For the same stocks of the Industry, the average monthly volume growth was -10% and the average quarterly volume growth was -21%

Fundamental Analysis Ratings

The average fundamental analysis ratings, where 1 is best and 100 is worst, are as follows

Valuation Rating: 50
P/E Growth Rating: 44
Price Growth Rating: 67
SMR Rating: 93
Profit Risk Rating: 93
Seasonality Score: -4 (-100 ... +100)
Real Time Patterns 3
View a ticker or compare two or three
Interact to see
Advertisement
A.I.Advisor
published price charts
A.I. Advisor
published General Information

General Information

a developer of novel immunotherapy biologic agents

Industry Biotechnology

Industry
Biotechnology
Address
1111 Kane Concourse
Phone
+1 781 652-4500
Employees
78
Web
https://www.fortressbiotech.com
Interact to see
Advertisement
UNH dropped -7.80% to $359.29 from Tuesday's $389.68 close, extending a two-session decline to roughly -13% and touching its lowest level in about seven weeks; the move occurred during regular market hours. The selloff accelerated on the CMS "CRUSH" proposal unveiled Nov. 16, which would extrapolate Medicare Advantage risk-adjustment audit findings from samples across entire contracts back to payment year 2018 and drop the fee-for-service adjuster; CMS estimates roughly $9 billion in industry clawbacks per payment year, and UnitedHealth, the largest MA insurer, has not sized its exposure.
SDD is an inverse leveraged ETF (exchange-traded fund) built to return roughly -2x the daily move of the S&P SmallCap 600 Index, making it a tactical hedging tool rather than a long-term holding. XXX is an asset-allocation ETF that blends roughly 75% S&P 500 large-cap equities with a 25% sleeve of XRP, a major cryptocurrency, aiming for capital appreciation.
AMD jumped +2.42%, rising $12.81 to $542.95 from Wednesday's close of $530.14, in early regular-session trading Thursday after extending gains built during premarket. The catalyst was Anthropic's IPO, priced at $83 a share above its marketed range and raising $81.3 billion in the largest listing on record; the debut revived sentiment across AI hardware names, and AMD is both an Anthropic supplier and a $2.5 billion investor in the lab.
Cerebras Systems (CBRS) dropped -6.48% to $97.43 in regular trading from the prior close of $104.18, reversing an early premarket gain of roughly +3%. No verified news or fundamental catalyst found for the intraday reversal; the move is likely profit-taking after the stock's +21% post-earnings rebound, consistent with a name that averages a ±4.5% daily swing and remains 65% below its first-day close.
ROM is an established, leveraged exchange-traded fund (ETF) that targets twice (2x) the daily return of the S&P Technology Select Sector Index, while XXX is a recently launched blended ETF pairing large-cap U.S. equities with XRP exposure. ROM benefits from deep liquidity and roughly $1.1 billion in AUM (assets under management); XXX remains far smaller, with assets measured in the hundreds of thousands of dollars.